20 research outputs found
Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor
Editorial Introduction to the Supplement “Diagnosis of Infectious Diseases by Detection of Microbial Pathogens: A Joint Session Between HemoSpec FrameWork 7 Consortium with COST Action BM1401 Raman4Clinics Working Group 2”
Early changes of the kinetics of monocyte trem-1 reflect final outcome in human sepsis
Background: TREM-1 (triggering receptor expressed on myeloid cells), a receptor expressed on neutrophils and monocytes, is upregulated in sepsis and seems to tune the inflammatory response. We explored the expression of TREM-1 at the gene level and on cell membranes of monocytes and association with clinical outcome. Methods: Peripheral venous blood was sampled from 75 septic patients (39 patients with sepsis, 25 with severe sepsis and 11 with septic shock) on sepsis days 1, 3 and 7. TREM-1 on monocytes was measured by flow cytometry; gene expression of in circulating mononuclear cells was assessed by real-time PCR. sTREM-1 was measured in serum by an enzyme immunoassay. Results: Although surface TREM-1, sTREM-1 and gene expression did not differ between sepsis, severe sepsis and septic shock on day 1, survivors had greater expression of surface TREM-1 on days 3 and 7 compared to non-survivors. sTREM-1 on non-survivors decreased on day 3 compared to baseline. Patients with increase of monocyte gene expression of from day 1 to day 3 had prolonged survival compared to patients with decrease of gene expression of from day 1 to day 3 (p: 0.031). Conclusions: Early decrease of gene expression of in monocytes is associated with poor outcome. A reciprocal decrease of the pro-inflammatory surface receptor TREM-1 linked with sepsis-induced immunosuppression may be part of the explanation. © Marioli et al
Early changes of the kinetics of monocyte trem-1 reflect final outcome in human sepsis
Background: TREM-1 (triggering receptor expressed on myeloid cells), a receptor expressed on neutrophils and monocytes, is upregulated in sepsis and seems to tune the inflammatory response. We explored the expression of TREM-1 at the gene level and on cell membranes of monocytes and association with clinical outcome. Methods: Peripheral venous blood was sampled from 75 septic patients (39 patients with sepsis, 25 with severe sepsis and 11 with septic shock) on sepsis days 1, 3 and 7. TREM-1 on monocytes was measured by flow cytometry; gene expression of in circulating mononuclear cells was assessed by real-time PCR. sTREM-1 was measured in serum by an enzyme immunoassay. Results: Although surface TREM-1, sTREM-1 and gene expression did not differ between sepsis, severe sepsis and septic shock on day 1, survivors had greater expression of surface TREM-1 on days 3 and 7 compared to non-survivors. sTREM-1 on non-survivors decreased on day 3 compared to baseline. Patients with increase of monocyte gene expression of from day 1 to day 3 had prolonged survival compared to patients with decrease of gene expression of from day 1 to day 3 (p: 0.031). Conclusions: Early decrease of gene expression of in monocytes is associated with poor outcome. A reciprocal decrease of the pro-inflammatory surface receptor TREM-1 linked with sepsis-induced immunosuppression may be part of the explanation. © Marioli et al
Randomized, controlled, multicentre clinical trial of the antipyretic effect of intravenous paracetamol in patients admitted to hospital with infection
Aim: No randomized study has been conducted to investigate the use of intravenous paracetamol (acetaminophen, APAP) for the management of fever due to infection. The present study evaluated a new ready-made infusion of paracetamol. Methods: Eighty patients with a body temperature onset ≥38.5°C in the previous 24 h due to infection were randomized to a single administration of placebo (n = 39) or 1 g paracetamol (n = 41), and their temperature was recorded at standard intervals. Rescue medication with 1 g paracetamol was allowed. Serum samples were collected for the measurement of APAP and its metabolites. The primary endpoint was defervescence, defined as a core temperature ≤37.1°C. Results: During the first 6 h, defervescence was achieved in 15 (38.5%) patients treated with placebo compared with 33 (80.5%) patients treated with paracetamol 1 g (P < 0.0001). The median time to defervescence with paracetamol 1 g was 3 h. Rescue medication was given to 15 (38.5%) and five (12.2%) patients allocated to placebo and paracetamol, respectively (P = 0.007); nine (60.0%) and two (40.0%) of these patients, respectively, experienced defervescence. No further antipyretic medication was needed for patients becoming afebrile with rescue medication. Serum glucuronide-APAP concentrations were significantly greater in the serum of patients who did not experience defervescence with paracetamol. The efficacy of paracetamol was not affected by serum creatinine. No drug-related adverse events were reported. Conclusions: The 1 g paracetamol formulation has a rapid and sustainable antipyretic effect on fever due to infection. Its efficacy is dependent on hepatic metabolism. © 2016 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society
Can procalcitonin monitoring reduce the length of antibiotic treatment in bloodstream infections?
Bloodstream infections and sepsis in Greece: over-time change of epidemiology and impact of de-escalation on final outcome
Background: Choice of empirically prescribed antimicrobials for sepsis
management depends on epidemiological factors. The epidemiology of
sepsis in Greece was studied in two large-periods.
Methods: Sepsis due to bloodstream infections (BSI) from July 2006 until
March 2013 was recorded in a multicenter study in 46 departments.
Patients were divided into sepsis admitted in the emergencies and
hospitalized in the general ward (GW) and sepsis developing after
admission in the Intensive Care Unit (ICU). The primary endpoints were
the changes of epidemiology and the factors related with BSIs by
multidrug-resistant (MDR) pathogens; the secondary endpoint was the
impact of de-escalation on antimicrobial therapy.
Results: 754 patients were studied; 378 from 2006-2009 and 376 from
2010-2013. Major differences were recorded between periods in the GW.
They involved increase of: sepsis severity; the incidence of underlying
diseases; the incidence of polymicrobial infections; the emergence of
Klebsiella pneumoniae as a pathogen; and mortality. Factors
independently related with BSI by MDR pathogens were chronic
hemofiltration, intake of antibiotics the last three months and
residence into long-term care facilities. De-escalation in BSIs by fully
susceptible Gram-negatives did not affect final outcome. Similar
epidemiological differences were not found in the ICU; MDR
Gram-negatives predominated in both periods.
Conclusions: The epidemiology of sepsis in Greece differs in the GW and
in the ICU. De-escalation in the GW is a safe strategy
Epidemiology and microbiology of sepsis in mainland China in the first decade of the 21st century
Procalcitonin to reduce long-term infection-associated adverse events in sepsis a randomized trial
Rationale: Although early antimicrobial discontinuation guided by procalcitonin (PCT) has shown decreased antibiotic consumption in lower respiratory tract infections, the outcomes in long-term sepsis sequelae remain unclear. Objectives: To investigate if PCT guidance may reduce the incidence of long-term infection-associated adverse events in sepsis. Methods: In this multicenter trial, 266 patients with sepsis (by Sepsis-3 definitions) with lower respiratory tract infections, acute pyelonephritis, or primary bloodstream infection were randomized (1:1) to receive either PCT-guided discontinuation of antimicrobials or standard of care. The discontinuation criterion was >80% reduction in PCT levels or any PCT <0.5 mg/L at Day 5 or later. The primary outcome was the rate of infection-associated adverse events at Day 180, a composite of the incidence of any new infection by Clostridioides difficile or multidrug-resistant organisms, or any death attributed to baseline C. difficile or multidrug-resistant organism infection. Secondary outcomes included 28-day mortality, length of antibiotic therapy, and cost of hospitalization. Measurements and Main Results: The rate of infection-associated adverse events was 7.2% (95% confidence interval [CI], 3.8–13.1%; 9/125) versus 15.3% (95% CI, 10.1–22.4%; 20/131) (hazard ratio, 0.45; 95% CI, 0.20–0.98; P = 0.045); 28-day mortality 15.2% (95% CI, 10–22.5%; 19/125) versus 28.2% (95% CI, 21.2–36.5%; 37/131) (hazard ratio, 0.51; 95% CI, 0.29–0.89; P = 0.02); and median length of antibiotic therapy 5 (range, 5–7) versus 10 (range, 7–15) days (P, 0.001) in the PCT and standard-of-care arms, respectively. The cost of hospitalization was also reduced in the PCT arm. Conclusions: In sepsis, PCT guidance was effective in reducing infection-associated adverse events, 28-day mortality, and cost of hospitalization. Copyright © 2021 by the American Thoracic Society